Chief R&D Officer

Protalix Biotherapeutics Karmiel, Israel

About the Protalix Biotherapeutics

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins with an initial focus on complex therapeutic proteins for the treatment of various therapeutics indications including, but not limited to, rare genetic disorders such as Gaucher disease and Fabry disease. Protalix has developed deep scientific, clinical, regulatory, and medical knowledge in the protein therapeutic field and applies novel protein engineering technologies that are combined with its proprietary ProCellEx® plant cell culture-based protein expression system, manufacturing and quality assurance expertise to develop innovative therapeutic products to meet patient needs around the world.
Track Record of Success
Protalix was founded by Dr. Yoseph Shaaltiel in 1993. Protalix demonstrated scientific achievements in the fields of biochemistry, molecular biology, cell line engineering, cell culture scale-up optimization and other critical expertise to support clinical and regulatory development up-to marketing approval.
Protalix is proud to be the first company to gain FDA approval for a plant cell culture expressed protein. Elelyso® (taliglucerase alfa for injection)- an enzyme replacement therapy for the treatment of Type 1 Gaucher Disease. Protalix is currently in late stage of its second ERT for Fabry disease.
Protalix plans to leverage its unique expertise in complex recombinant therapeutic protein drug development. Its strategic intent is to partner on the creation and development of new innovative medical therapies synergizing the competencies of both.
Pipeline products will be anchored to Protalix’s core skills and expertise in therapeutic protein-based drug development as well as building upon their protein engineering and modification capabilities that have been internally developed to improve the biologic dynamics (e.g., glycosylation, chemical modification, half-life extension) of therapeutic proteins which have underpinned the successes of the current pipeline.
Vision and Strategy
Protalix’s vision is to become a fully integrated biopharmaceutical company focused on developing therapies by leveraging medical, clinical, and regulatory expertise gained from our Gaucher and Fabry Disease programs combined with internal therapeutic protein research and development capabilities and expertise.  Protalix will continue to evolve and innovate through the integration and application of novel protein engineering technologies and new modes of disease treatment including gene therapies by actively collaborating with leading academic researchers and biotech companies around the world.

Pipeline Overview
With the therapeutic protein for Fabry disease now in the FDA approval process, Protalix is now advancing early-stage programs.
You can find further details on their website https://protalix.com/

Chief R&D Officer Role Profile

The Chief R&D Officer will have a strategic view of market opportunities for the therapies offered by Protalix, identifying prospects to populate a pipeline of innovative products, which capitalizes on Protalix’s previous successes in the field of therapeutic proteins. S/he will be responsible for taking such opportunities through the complete cycle of R&D.

Duties and Responsibilities

The Chief R&D Officer will manage all R&D projects and overall activities of the associated clinical and regulatory programs. This will include:
  • Lead and manage the senior team members of the R&D departments
  • Enrich the pipeline and identify and evaluate new technology pertaining to the company pipeline
  • Work with the CEO, senior management and board of directors of the company, as well as external stakeholders (scientific and investors communities) in developing and execution of strategic development roadmap
  • Leading and coordinating project planning and worldwide execution of all external and internal resources achieving successful execution in a timely manner.

Qualifications and Experience

  • Ph.D. in life sciences and/or MD with strong scientific experience.
  • At least 10 years in industrial set-up in leading protein therapeutic development and in-depth knowledge in the most advanced protein developments
  • Strong background in biochemistry and/or molecular biology (plant science would be an advantage)
  • Strong experience in cell cultures-based development of recombinant therapeutic including small scale industrial process development
  • Substantial experience and deep understanding of Clinical and regulatory requirements based on a scientific profile of the developed programs
  • Global experience
  • Strong mentor/leadership capabilities with team building as a core focus
  • Ability to advance programs in a balanced way (creativity & risk evaluation)
  • Strategic and visionary thinking.
  • Relationship building within the medical, pharmaceutical and biotechnology communities.
  • Strong presentation and communications skills.
  • Excellent English (oral and written).

Location: Karmiel, Israel

This role could be based on site but equally working remotely with significant on-site presence would be a possibility.

How to Apply

If you wish to be considered for this position, please complete the Application Form below on or before 21 October 2021. In addition, we encourage you to please attach a copy of the most recent English version of your CV.

All information will be treated in the strictest confidence as we pride ourselves on our professional service.

If you have an initial query rather than an application, kindly email us at [email protected].

Application form

Personal Details


Work Experience